Clinical trials: Relapsed
Purpura, Thrombocytopenic, Idiopathic
Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
The purpose of this study is to determine whether Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab prednisone are effective and safe in the management of Steroid-Resistant/Relapsed Immune Thrombocytopenia…
- Trial name
- Incritop (NCT01317966)
- Testing
- rhIL-11
- Where
- China
- Sponsor
- Ming Hou
AML
Evaluate the Safety and Efficacy of CLL1 CAR-T in Patients With R/R AML
This is an open label, phase I study to assess the safety and efficacy of CLL1 CAR-T in patients with relapsed and refractory acute myeloid leukemia
- Trial name
- NCT05467202
- Testing
- CLL1 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
T-Cell Neoplasm, Lymphoproliferative Disorders
Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
- Trial name
- NCT04858256
- Testing
- Pacritinib
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Michigan Rogel Cancer Center
Repeatedly Recurring Esophagitis, Relapsing Reflux Esophagitis
Nexium Capsules RE Maintenance Specific Clinical Experience Investigation
The purpose of this study is to collect following data in patients given Nexium capsule (Nexium) in usual post-marketing use as the maintenance therapy for repeatedly recurring/relapsing reflux oesophagitis.
- Trial name
- NCT01562639
- Where
- 46 sites in Japan
- Volunteers
- 647 people
- Sponsor
- AstraZeneca
Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat…
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Diffuse Large B Cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- NCT06458439
- Testing
- Epcoritamab
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a…
- Trial name
- NCT07221500
- Testing
- NX-5948
- Where
- 43 sites in United States, France and 3 more
- Volunteers
- 100 people
- Sponsor
- Nurix Therapeutics, Inc.
EWINGS SARCOMA
Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma
The purpose of this study is to examine the toxicity of using allogeneic stem cell transplantation for treatment of subjects with relapsed or refractory ES and rhabdomyosarcoma.
- Trial name
- Ewing/Allo (NCT02472392)
- Testing
- Rabbit anti-thymocyte globulin, Busulfan, Melphalan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Louisville
Relapsing-Remitting Multiple Sclerosis
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality
Since many years cognitive disorders are a main topic of clinical research in Multiple Sclerosis (MS) as there could be observed early on in the disease and could induce with time in patients significant socio-professional…
- Trial name
- SEPREV (NCT01805336)
- Testing
- Assessment of attentional functions by traditional tests, Assessment of attentional functions by virtual reality tests, Assessment of executive functions by traditional tests
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Relapsed or Refractory Multiple Myeloma
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of forimtamig when administered alone or in combination with carfilzomib or daratumumab or other combination partners in…
- Trial name
- NCT06055075
- Testing
- Forimtamig, Carfilzomib, Daratumumab
- Where
- 8 sites in Australia, Canada and 4 more
- Volunteers
- 21 people
- Sponsor
- Hoffmann-La Roche
Unrecognized Condition
DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors
Doxorubicin is an anthracycline antibiotic that is part of the standard treatment for many pediatric malignancies, but its long-term cardiotoxicity cannot be ignored.
- Trial name
- NCT04213612
- Testing
- pegylated liposomal doxorubicin, cyclophosphamide, vincristine,
- Volunteers
- 21 people
- Sponsor
- Sun Yat-sen University
Multiple Myeloma
Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of BCMA-PD1-CART cells therapy for patients with relapsed/refractory Multiple Myeloma.
- Trial name
- NCT04162119
- Testing
- BCMA-PD1-CART Cell
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Multiple Myeloma
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb).
- Trial name
- DREAMM12 (NCT04398745)
- Testing
- Belantamab mafodotin
- Where
- 4 sites in Greece, South Korea
- Volunteers
- 36 people
- Sponsor
- GlaxoSmithKline
Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r…
- Conditions
- Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia
- Trial name
- NCT04030195
- Testing
- PBCAR20A, Fludarabine, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Precision BioSciences, Inc.
Relapsing Remitting Multiple Sclerosis
Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis
The purpose of this study is to determine whether raltegravir is effective in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium- enhanced MRI.
- Trial name
- INSPIRE (NCT01767701)
- Testing
- Raltegravir
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Queen Mary University of London
Parkinson s Disease, Tremor
MRgFUS for Parkinson's Tremor
This study investigates magnetic resonance-guided focused ultrasound thalamotomy (MRgFUSth) for people with Parkinson's disease (PD) and tremor not responding to conventional standard doses of dopamine replacement therapy.
- Trial name
- NCT07284719
- Testing
- MR-guided focused ultrasound thalamotomy
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Aarhus University Hospital
Hodgkin's Lymphoma
Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory
PET-based consolidation and donor-based therapy after rescue in patients with Hodgkin's lymphoma refractory at first line therapy, or relapse early or late, undergone a second line chemotherapy.
- Trial name
- NCT00879528
- Testing
- Patients with negative PET after salvage therapy, Patients with positive PET after salvage therapy
- Where
- 39 sites in Italy
- Volunteers
- 264 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Diffuse Large B-cell Lymphoma
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
To evaluate the real-world efficacy of Tafasitamab combined with Lenalidomide base regimen in patients with relapsed or refractory DLBCL, with objective response rate as the primary end point.
- Trial name
- NCT05883709
- Testing
- Tafasitamab Injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhao Weili
Smoking, Low Physical Activity Level
Perfect Fit: Evaluation of a Virtual Coach for Smoking Cessation and Physical Activity
The leading cause of disease burden across the globe is cardiovascular disease (CVD). Important modifiable behavioral CVD risk factors include, amongst others, smoking and low physical activity (PA).
- Trial name
- NCT06095999
- Testing
- Perfect Fit intervention: virtual coaching intervention to quit smoking and increase physical activity
- Where
- Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects, best dose of flotetuzumab and how well it works in treating patients with acute myeloid leukemia (AML) that has come back (recurrent) or has not responded to treatment (refractory).
- Trial name
- NCT04158739
- Testing
- Cytarabine, Flotetuzumab
- Where
- 19 sites in United States
- Volunteers
- 16 people
- Sponsor
- Children's Oncology Group
Lupus Erythematosus, Systemic Lupus Erythematosus
Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)
SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.
- Conditions
- Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06294236
- Testing
- SC291
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Sana Biotechnology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.